What changed: Hypopharyngeal cancer

Cancer page →

Every dated change on the records linked to Hypopharyngeal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result5Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHypopharyngeal cancer
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 3

2025Trial resultKEYNOTE-689
KEYNOTE-689 reported
Median EFS 59.
2025Trial resultNIVOPOSTOP (GORTEC 2018-01)
NIVOPOSTOP (GORTEC 2018-01) reported
Three-year disease-free survival 63.
2025MilestoneNIVOPOSTOP (GORTEC 2018-01)
NIVOPOSTOP: nivolumab after surgery for high-risk disease
A milestone in how this cancer is treated.

2019 · 2

2019Trial resultKEYNOTE-048
KEYNOTE-048 reported
OS 14.
2019MilestoneKEYNOTE-048
KEYNOTE-048: pembrolizumab first line in recurrent disease
A milestone in how this cancer is treated.

2006 · 2

2006Trial resultBonner trial (cetuximab plus radiotherapy)
Bonner trial (cetuximab plus radiotherapy) reported
Median overall survival 49.
2006MilestoneBonner trial (cetuximab plus radiotherapy)
Cetuximab with radiotherapy (Bonner) includes hypopharyngeal tumours
A milestone in how this cancer is treated.

2003 · 2

2003Trial resultRTOG 91-11
RTOG 91-11 reported
Larynx preservation at 2 years 88% (concurrent) vs 75% (induction) vs 70% (radiotherapy alone).
2003MilestoneRTOG 91-11
RTOG 91-11: concurrent cisplatin chemoradiation preserves the larynx best
A milestone in how this cancer is treated.

1996 · 1

1996MilestoneHypopharyngeal cancer
EORTC 24891: induction chemotherapy and radiotherapy preserve the larynx without loss of survival
A milestone in how this cancer is treated.